Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nitric oxide synthase 2, inducible | Starlite/ChEMBL | References |
Homo sapiens | nitric oxide synthase 1 (neuronal) | Starlite/ChEMBL | References |
Homo sapiens | nitric oxide synthase 3 (endothelial cell) | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0091 | 1 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0081 | 0.7743 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0091 | 1 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0045 | 0 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0056 | 0.2407 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0081 | 0.7743 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0091 | 1 | 1 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0091 | 1 | 0.5 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0091 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0091 | 1 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0091 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0091 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0091 | 1 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0091 | 1 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0045 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0091 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0091 | 1 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0056 | 0.2407 | 0.2407 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0091 | 1 | 0.5 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0091 | 1 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0091 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0091 | 1 | 0.5 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0046 | 0.0151 | 0.0151 |
Brugia malayi | FAD binding domain containing protein | 0.0091 | 1 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0091 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0091 | 1 | 0.5 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0091 | 1 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0091 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0091 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.5 uM | Inhibitory activity against Inducible nitric oxide synthase | ChEMBL. | 15357988 |
IC50 (binding) | = 0.5 uM | Inhibitory activity against Inducible nitric oxide synthase | ChEMBL. | 15357988 |
IC50 (binding) | = 2.6 uM | Inhibitory activity against Neuronal nitric oxide synthase | ChEMBL. | 15357988 |
IC50 (binding) | = 2.6 uM | Inhibitory activity against Neuronal nitric oxide synthase | ChEMBL. | 15357988 |
IC50 (binding) | = 3.4 uM | Inhibition of iNOS (unknown origin) | ChEMBL. | 18357974 |
IC50 (binding) | = 3.4 uM | Inhibition of iNOS (unknown origin) | ChEMBL. | 18357974 |
IC50 (binding) | = 14.5 uM | Inhibitory activity against Endothelial nitric oxide synthase | ChEMBL. | 15357988 |
IC50 (binding) | = 14.5 uM | Inhibitory activity against Endothelial nitric oxide synthase | ChEMBL. | 15357988 |
Ratio (binding) | = 4.8 uM | Ratio between Neuronal nitric oxide synthase and Inducible nitric oxide synthase | ChEMBL. | 15357988 |
Ratio (binding) | = 27 uM | Ratio between Endothelial nitric oxide synthase and Inducible nitric oxide synthase | ChEMBL. | 15357988 |
Ratio (binding) | = 27 uM | Ratio between Endothelial nitric oxide synthase and Inducible nitric oxide synthase | ChEMBL. | 15357988 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
2 literature references were collected for this gene.